OBJECTIVE： To observe the clinical efficacy of qianliexin combined with tamsulosin hydrochloride and finasteride in the treatment of elderly benign prostatic hyperplasia. METHODS： Ninety-four patients diagnosed as benign prostatic hyperplasia in our hospital during May. 2012-Oct. 2014 were selected and divided into observation group （48 cases） and control group （46 cases） according to even and odd admission number. Both groups received Finasteride tablet 5 mg， po， qd. Basedon this， control group was additionally given Tamsulosin hydrochloride sustained-release capsules 0.2 mg， po， qd； observation group was additionally given Qianliexin capsules 2.5 g， po， tid， on the basis of control group. Clinical efficacies of 2 groups were observed as well as IPSS， BS， IIEF-5 score， ultrasonic measurement indexes and TCM syndrome score before and after treatment. RESULTS： Clinical total response rate of observation group was 93.75％， which was significantly higher than 76.09％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in IPSS， BS， IIEF-5 score， ultrasonic measurement indexes and TCM syndrome score between 2 groups （P＞0.05）. After treatment， IPSS and BS score， prostate volume （PV）， residual urine（RU）， each item score and total score of TCM syndrome were significantly decreased in 2 groups， while IIEF-5 score and Qmax were increased significantly； the observation group was significantly better than the control group， with statistical significance（P＜0.05）. CONCLUSIONS： Qianliexin combined with tamsulosin hydrochloride and finasteride shows significant therapeutic efficacy for elderly benign prostatic hyperplasia， and is helpful to improve prostate symptoms and TCM syndromes， reduce PV and RU， and improve sexual function.